A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To learn if olutasidenib can help to control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z potwierdzonymi chorobami CCUS, MDS lub CMML.
- •Pacjenci muszą mieć stwierdzoną mutację IDH1.
- •Pacjenci muszą mieć ukończone 18 lat.
- •Ogólny stan zdrowia pacjentów musi być dobry (niezależność od pomocy innych w codziennych czynnościach).
- •Wyniki badań krwi (bilirubina, wątrobowe enzymy, czynność nerek) muszą mieścić się w określonych normach.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
University of Miami
Miami, United States
MD Anderson Cancer Center
Houston, United States
Trial contact
Kelly Chien, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.